在癌症治疗中使用端粒酶
Silvia Siteni1, Anthony Grichuk1, Jerry W Shay2
1University of Texas Southwestern Medical Center, Department of Cell Biology, Dallas, Texas 75390, USA jerry.shay@utsouthwestern.edu.
端粒酶在大多数癌症中被重新激活,是瘤学的关键目标. 本综述涵盖了各种临床前和临床策略,包括抑制剂和疫苗,其中一些接近晚期发展阶段.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 端粒酶在正常人体组织中通常是静态的,但在大多数人类癌症中会被重新激活.
- 这种重新激活使得端粒酶成为癌症治疗的几乎普遍目标.
研究的目的:
- 审查针对癌症治疗的端粒酶的临床前和临床进展.
- 讨论各种治疗方法及其优缺点.
主要方法:
- 对直接端粒酶抑制剂的审查.
- 对G-四复数DNA相互作用连接体的分析.
- 基于端粒酶的疫苗平台的评估.
- 对端粒酶促进体驱动的减弱病毒的评估.
- 检查端粒酶介导的端粒向策略.
主要成果:
- 一种端粒酶抑制剂Imetelstat获得了FDA的批准.
- 其他几种针对端粒酶的方法正在临床开发的后期阶段.
- 该综述详细介绍了主要治疗策略的优缺点.
结论:
- 向端粒酶仍然是瘤学中一个有前途的战略.
- 不同的治疗方式正在进步,为癌症患者提供了新的希望.
- 持续的研究和开发对于优化端粒酶向疗法至关重要.
更多相关视频
09:13Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells
Published on: January 17, 2019
06:38Droplet Digital TRAP ddTRAP: Adaptation of the Telomere Repeat Amplification Protocol to Droplet Digital Polymerase Chain Reaction
Published on: May 3, 2019
相关概念视频
Replicative Cell Senescence
Telomeres and Telomerase
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
